These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 39269573)

  • 21. Determination of the motor status of patients with advanced Parkinson's disease under levodopa-carbidopa intestinal gel using a machine learning model.
    Efthymiopoulou E; Antonoglou A; Loupo B; Bougea A
    Acta Neurol Belg; 2023 Apr; 123(2):565-570. PubMed ID: 36472797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levodopa-Carbidopa-Entacapone Intestinal Gel in Advanced Parkinson Disease: A Multicenter Real-Life Experience.
    Szász JA; Dulamea AO; Constantin VA; Mureşanu DF; Dumbravă LP; Tiu C; Jianu DC; Simu M; Ene A; Axelerad A; Falup-Pecurariu C; Lungu M; Danci AG; Sabau M; Strilciuc Ş; Popescu BO
    Am J Ther; 2024 May-Jun 01; 31(3):e209-e218. PubMed ID: 38460175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rescue levodopa-carbidopa intestinal gel (LCIG) therapy in Parkinson's disease patients with suboptimal response to deep brain stimulation.
    Elkouzi A; Ramirez-Zamora A; Zeilman P; Barabas M; Eisinger RS; Malaty IA; Okun MS; Almeida L
    Ann Clin Transl Neurol; 2019 Oct; 6(10):1989-1995. PubMed ID: 31518070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
    Zulli C; Sica M; De Micco R; Del Prete A; Amato MR; Tessitore A; Ferraro F; Esposito P
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2413-7. PubMed ID: 27338069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levodopa-carbidopa intrajejunal infusion in Parkinson's disease: untangling the role of age.
    Morgante F; Oppo V; Fabbri M; Olivola E; Sorbera C; De Micco R; Ielo GC; Colucci F; Bonvegna S; Novelli A; Modugno N; Sensi M; Zibetti M; Lopiano L; Tessitore A; Pilleri M; Cilia R; Elia AE; Eleopra R; Ricciardi L; Cossu G
    J Neurol; 2021 May; 268(5):1728-1737. PubMed ID: 33354739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient preference of device-based treatment of Parkinson's disease.
    Aydemir ST; Kumcu MK; Ulukan Ç; Bakirarar B; Akbostancı MC
    Int J Neurosci; 2022 Sep; 132(9):925-929. PubMed ID: 33208012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson's Disease: A Systematic Review and Bayesian Network Meta-analysis.
    Antonini A; Pahwa R; Odin P; Isaacson SH; Merola A; Wang L; Kandukuri PL; Alobaidi A; Yan CH; Bao Y; Zadikoff C; Parra JC; Bergmann L; Chaudhuri KR
    CNS Drugs; 2022 Dec; 36(12):1269-1283. PubMed ID: 36414908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study.
    Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Solla P; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Zangaglia R; Bentivoglio A; Eleopra R; Gualberti G; Melzi G; Antonini A
    J Neurol; 2019 Sep; 266(9):2164-2176. PubMed ID: 31134377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levodopa/carbidopa intestinal gel infusion and weight loss in Parkinson's disease.
    Fabbri M; Zibetti M; Beccaria L; Merola A; Romagnolo A; Montanaro E; Ferreira JJ; Palermo S; Lopiano L
    Eur J Neurol; 2019 Mar; 26(3):490-496. PubMed ID: 30347489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK.
    Lowin J; Bergman A; Chaudhuri KR; Findley LJ; Roeder C; Schifflers M; Wood E; Morris S
    J Med Econ; 2011; 14(5):584-93. PubMed ID: 21728911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Wang L; Li J; Chen J
    Front Neurol; 2018; 9():620. PubMed ID: 30104997
    [No Abstract]   [Full Text] [Related]  

  • 32. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.
    Antonini A; Yegin A; Preda C; Bergmann L; Poewe W;
    Parkinsonism Relat Disord; 2015 Mar; 21(3):231-5. PubMed ID: 25585993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
    Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
    Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advanced therapies in Parkinson's disease: an individualized approach to their indication.
    Schröter N; Sajonz BEA; Jost WH; Rijntjes M; Coenen VA; Groppa S
    J Neural Transm (Vienna); 2024 Nov; 131(11):1285-1293. PubMed ID: 38613674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: Observations and Dilemmas after 10 Years of Real-Life Experience.
    Szász JA; Constantin VA; Orbán-Kis K; Bancu LA; Bataga SM; Ciorba M; Nagy E; Neagoe MR; Mihály I; Szász RM; Kelemen K; Simu M; Szatmári S
    Pharmaceutics; 2022 May; 14(6):. PubMed ID: 35745688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients.
    Antonini A; Abbruzzese G; Berardelli A; Modugno N; Stroppa I; Tamma F; Sensi M; Mancini F; Cossu G; Stefani A; Tambasco N; Tessitore A; Fabbrini G; Pontieri FE; Solla P; Bentivoglio AR; Comi C; Minafra B; Riboldazzi G; Melchionda D; Martino T; Lopiano L
    J Neural Transm (Vienna); 2020 Jun; 127(6):881-891. PubMed ID: 32212015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson's disease.
    Fabbri M; Pongmala C; Artusi CA; Romagnolo A; Rizzone MG; Zibetti M; Lopiano L
    Acta Neurol Scand; 2019 Aug; 140(2):157-161. PubMed ID: 31025312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parkinson's Disease: Personalized Pathway of Care for Device-Aided Therapies (DAT) and the Role of Continuous Objective Monitoring (COM) Using Wearable Sensors.
    Metta V; Batzu L; Leta V; Trivedi D; Powdleska A; Mridula KR; Kukle P; Goyal V; Borgohain R; Chung-Faye G; Chaudhuri KR
    J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson's disease: results of the Italian GLORIA patient population.
    Antonini A; Marano P; Gusmaroli G; Modugno N; Pacchetti C; Sensi M; Melzi G; Bergmann L; Zibetti M; Lopiano L
    Neurol Sci; 2020 Oct; 41(10):2929-2937. PubMed ID: 32342325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of device-assisted therapies on the gut microbiome in Parkinson's disease.
    Lubomski M; Xu X; Holmes AJ; Yang JYH; Sue CM; Davis RL
    J Neurol; 2022 Feb; 269(2):780-795. PubMed ID: 34128115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.